History

Established in 2005 through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo has a rich history spanning more than 100 years.

History of Sankyo Co., Ltd. Year History of Daiichi Pharmaceutical Co., Ltd.
  • Founded as Sankyo Shoten through a joint investment by businessmen Matasaku Shiobara, Shotaro Nishimura and Genjiro Fukui
  • Launched digestive enzyme Taka-Diastase® (in 1894, Dr. Jokichi Takamine discovered the enzyme from a fungus)
1899   -
  • Launched Adrenalin®, an adrenal cortex hormone agent
1902   -
  • Established plant in Shinagawa, Japan
1908   -
  • Dr. Umetaro Suzuki, a future Sankyo scientific adviser, made the world's first discovery of vitamin B1 (Orizanin®) in rice bran and established a foundation for the theory of vitamins
1910   -
  • Changed company name from Sankyo Shoten to Sankyo Co., Ltd.
  • Appointed Dr. Jokichi Takamine as first president
1913   -
  - 1915

  • Founded as Arsemin Shokai by Dr. Katsuzaemon Keimatsu and five others
  • Launched Arsemin®, an antisyphilitic agent
  - 1916
  • Launched Neo-Arsemin®, another antisyphilitic agent
  - 1918
  • Changed company name from Arsemin Shokai to Daiichi Pharmaceutical Co., Ltd.
  • Appointed Seinosuke Shibata as first president
  • Began manufacturing Japan's first synthetic agricultural chemical, the fumigant insecticide KOKUZOL®
1921
  • Launched Bosmin®, a vasoconstriction / hemostasis and asthma medicine
  - 1933
  • Established plant in Takatsuki, Japan
  - 1937
  • Launched Therapol®, the first sulfa drug produced in Japan
  - 1938
  • Established plant in Funabori, Japan
 
  • Listed on Tokyo Stock Exchange
1949  
  • Listed on Tokyo Stock Exchange

  • Launched LULU® cold medicine
  • Manufactured Chloromycetin®, the first antibiotic produced in Japan
1951   -
  - 1952
  • Launched Iscotin®, a medicine for tuberculosis
  • Launched Sankyo Ichoyaku (now Daiichi Sankyo Ichoyaku)
1957   -
    1965
  • Completed construction of head office building in Nihonbashi, Japan
  • Launched Vitamedin®, a vitamin B1, B6 and B12 compound
  • Launched Transamin®, an antiplasmin medicine
 
  • Established plant in Hiratsuka, Japan
1966
  • Launched Patecs®, the first form-fitting pain relief patch
  - 1973
  • Launched Karoyan®, a hair restoration agent
  • Launched Krestin®, an anticancer drug
1977   -
  - 1979
  • Launched Neuer®, a peptic ulcer agent
  • Launched Cefmetazon®, a cephamycin-type antibiotic
1980   -
  - 1981
  • Established plant in Akita, Japan
  • Launched Captoril®, the world's first renin-angiotensin-type hypertensive drug
1983
  • Signed out-licensing agreement for Tarivid®, a broad-spectrum antibacterial agent, with Johnson & Johnson of the United States and Hoechst of Germany
  • Launched Zantac®, a therapeutic agent for peptic ulcers
1984   -
  • Established Sankyo USA Corporation in New York City
  • Established Sankyo Europe GmbH in Dusseldorf, Germany
1985
  • Launched natural-type interferon-β formulation Feron®
   
  • Launched Tarivid® in Japan and then-West Germany
  • Launched Loxonin®, an analgesic and anti-inflammatory agent
1986   -
  • Established plant in Onahama, Japan
1987
  • Launched Omnipark®, a contrast media
   
  • Launched Senlock Pellet® (now Daiichi Sankyo Core Block®), a gastrointestinal agent
  • Launched Regain®, a mini-bottled vitamin tonic
1988   -

  • Globally launched Mevalotin®, a groundbreaking HMG-CoA reductase inhibitor (hyperlipidemic drug)
  • Launched Banan®, an antibiotic
1989   -
  • Invested in Luitpold-Werk GmbH Group
1990  
  • Established Korea Daiichi Pharmaceutical Co., Ltd.
  • Awarded the Ohkochi Memorial Grand Production Prize for Mevalotin®
1992   -
  - 1993
  • Launched Cravit®, a broad-spectrum oral antibacterial agent
  • Completed construction of head office building in Nihonbashi, Japan
1994
  • Launched Kuromaru Drink®, a digestive tonic
  • Launched Acecol®, an antihypertensive agent
   
  • Established Sankyo Pharma Inc. in New Jersey, United States
1996   -
  • Became the first pharmaceutical company in Japan to receive ISO 14001 environmental certification for its Onahama and Odawara plants
  • Established Sankyo Pharma Research Institute in California, United States for the development of new medicines
1998  
  • Established Daiichi Pharmaceutical (Beijing) Co., Ltd. in China
  • Launched Fastic®, a drug for lowering blood sugar
2002   -

  • Launched Olmesartan (Benicar® in the United States and Olmetec® in Germany), an antihypertensive agent
   
    2003
  • Launched Cystina C®, an over-the-counter vitamin C product
  • Launched Calblock®, a long-acting calcium channel blocker
   
  • Launched Olmesartan in Japan
2004    
Year History of Daiichi Sankyo Co., Ltd.
2005
  • Established by joint holding company of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd.
2006
  • Began operations of Daiichi Sankyo Healthcare Co., Ltd.; Daiichi Sankyo, Inc.; and Daiichi Sankyo Europe GmbH
  • Launched Urief®, a drug for dysuria (Daiichi Pharmaceutical Co., Ltd.)
2007
  • Began operations on April 1, 2007 as Daiichi Sankyo Co., Ltd.
2008
  • Acquired U3 Pharma GmbH of Germany and Ranbaxy Laboratories Ltd. of India
2009
  • Launched Prasugrel, an antiplatelet agent and global product, in Germany (as Efient®) and the United States (as Effient®)
2010
  • Launched Rezaltas®, a high-affinity ARB/long-acting calcium antagonist compound
 
  • Began operations of Daiichi Sankyo Espha Co., Ltd.
  • Launched Inavir®, an anti-influenza virus agent
2011
  • Acquired Plexxikon Inc. of the United States
  • Began operations of Kitasato Daiichi Sankyo Vaccine Co., Ltd.
  • Launched Memary® for treatment of Alzheimer's disease
  • Launched Lixiana®, an oral FXa inhibitor
  • Launched Nexium®, a proton pump inhibitor
  • Consolidated Japan head office and head offices of Japan Group companies into three office buildings in the Nihonbashi area of Tokyo, Japan
 
  • Established wholly-owned subsidiary Daiichi Sankyo (China) Holdings Co., Ltd.
2012
  • Opened Daiichi Sankyo Kusuri Museum in Tokyo
  • Launched RANMARK®, an antibody that targets RANK ligand
  • Began operations of Japan Vaccine Co., Ltd., a joint venture with GlaxoSmithKline K.K.
  • Launched TENELIA®, a therapeutic agent for type 2 diabetes
2013
  • Launched natural tetrahydrobiopterin agent Biopten® Granules 10%
2014
  • Launched oral antiplatelet agent Efient in Japan
  • Launched CANAGLU® Tablets 100mg for treatment of Type 2 Diabetes Mellitus
  • Received approval in Japan for additional AF and VTE indications for LIXIANA® (edoxaban)
 
  • Acquired biopharmaceutical company Ambit Biosciences
2015
  • Launched edoxaban, an oral, once-daily anti-coagulant global product, in the United States (as SAVAYSA®) and in Europe (as LIXIANA®)
  • Launched Methylene Blue Injection 50mg, a treatment for methemoglobinemia
  • Launched MOVANTIK®, a treatment for opioid-induced constipation (OIC), in the United States via co-commercialization agreement with AstraZeneca
 
  • Ranbaxy Laboratories Limited acquired by Sun Pharmaceutical Industries Ltd. via all-stock transition
  • Daiichi Sankyo Healthcare acquired mail-order cosmetics and health food business, Im Co., Ltd.
  • Launched Squarekids® subcutaneous injection syringe, a tetravalent combination vaccine for the prevention of diphtheria, pertussis, tetanus, and poliomyelitis (polio)

Company Profile

As a global company, we aim to constantly extend our business activities.